Long-term treatment with disodium cromoglycate does not alter bronchial hyperreactivity in patients with perennial bronchial asthma

Respiration; International Review of Thoracic Diseases
P HaberO C Burghuber

Abstract

The purpose of this study was to examine whether a 3-month therapy with disodium cromoglycate (DSCG) is able to lower bronchial hyperreactivity in patients with perennial bronchial asthma and hyperreactive airways. Therefore, 24 patients with this condition (11 women, 13 men; age range from 16 to 41 years) were randomly allocated to either active treatment (20 mg DSCG four times daily) or to placebo in a prospectively designed, double-blind study. Bronchial hyperreactivity was assessed by acetylcholine-induced bronchoconstriction before and after 6 and 12 weeks of either DSCG or placebo treatment, respectively. As test values, the variations in FEV1 and oscillatory resistance (Ros) before and after inhaled acetylcholine was used. Despite the fact that DSCG significantly attenuated acetylcholine-induced acute bronchoconstriction in all patients studied, it did not exhibit a significant reduction in bronchial hyperreactivity in this patient population.

Citations

Oct 10, 2008·The Cochrane Database of Systematic Reviews·Johannes C van der WoudenFrancine Ducharme

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.